(Q36383819)

13 August 2017

1 reference

title

Molecular approaches for new vaccines against allergy (English)

1 reference

13 August 2017

2

Rudolf Valenta

1 reference

13 August 2017

Verena Niederberger

1

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Expert Review of Vaccines

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

103-110

1 reference

Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Recombinant allergen molecules: tools to study effector cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

From allergen structure to new forms of allergen-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Immunotherapy of allergic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Noninjection routes for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Sublingual immunotherapy for allergic rhinoconjunctivitis--the seeming and the real

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Discontinuing venom immunotherapy: outcome after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Renaissance of the blocking antibody concept in type I allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Systemic reactions to immunotherapy: influence of composition and manufacturer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Endotoxin content of standardized allergen vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Specific immunotherapy - the induction of new IgE-specificities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Structure and biology of stinging insect venom allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

The spectrum of olive pollen allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Characterization and immunobiology of house dust mite allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Immunobiology of fungal allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Characteristics and immunobiology of grass pollen allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

The allergens of Parietaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Vaccination with genetically engineered allergens prevents progression of allergic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.1.103

21 January 2018

Identifiers

DOI

10.1586/14760584.5.1.103

1 reference

13 August 2017

1 reference